"Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline 2025"Adeno-Associated Virus (AAV) Vectors in Gene Therapy companies are Nanoscope Therapeutics, REGENXBIO, Astellas Gene Therapy, ...

The non-viral transfection reagents market presents growth opportunities driven by the demand for cost-effective, low-immunogenicity alternatives to viral vectors, particularly for nucleic acid-based ...

The Xevo CDMS enhances analysis of large biomolecules, crucial for next-gen therapeutics, using individual-particle mass measurement for molecules up to 150+ MDa. Electrostatic Linear Ion Trap (ELIT) ...

After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of ...

Huntington’s disease has been treated for the first time. The genetic disease has no cure or currently approved treatments, but the company uniQure developed and tested a drug, known as AMT-130, on 29 ...

Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of ...

(MENAFN- GlobeNewsWire - Nasdaq) The AAV vector market is advancing due to the rising demand for gene therapies targeting disease causes at the cellular level. Key opportunities include increased ...

A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors.

Polyethyleneimines (PEIs) are extensively researched as non-viral vectors for gene and medication delivery because of their ...

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with ...

Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better treatment ...